The UK is Restarting a Puberty Blocker Trial Despite 25 Years of Evidence - Carrie Clark (#4)
While Sweden, Finland and Denmark have already restricted puberty blockers for minors, the NHS is preparing to launch a £10 million study that risks replicating the very errors European health authorities have spent years correcting. Carrie Clark of Genspect UK breaks down the Pathways study's methodology, its roots in the discredited Dutch Protocol, and why the rest of Europe should be watching closely.
When Sweden's Karolinska Hospital and Finland's Council for Choices in Health Care concluded that puberty blockers offered uncertain benefit and clear risk, the expectation in many European clinical circles was that the UK would move in a similar direction. The Cass Review, published in 2024, seemed to confirm that trajectory. Yet months later, NHS England is preparing to fund a major new research programme — the Pathways study — that would place thousands of gender-distressed children back into an experimental medical pathway. Carrie Clark, Director of Genspect UK, joins Stella O'Malley and Mia Hughes to examine exactly what that study involves and why its design raises serious questions. Clark explains that the Pathways study is structured around four research strands and carries a budget of approximately ten million pounds. Its premise, she argues, is shaped from the outset by activist framing rather than clinical neutrality. There are no meaningful exclusion criteria for children with co-occurring mental health conditions or autism — groups that made up a significant proportion of those seen at the now-closed Tavistock GIDS clinic. For European clinicians who followed the Cass Review's recommendation to treat psychological complexity before pursuing medical intervention, this absence is not a minor oversight but a fundamental methodological failure. The Dutch Protocol sits at the heart of this conversation. The protocol, developed at Amsterdam's VU Medical Centre in the 1990s, became the template for almost every gender clinic in Western Europe and North America. Clark and her hosts revisit its original selection criteria — strict, narrow, excluding children with significant psychiatric comorbidities — and trace how those criteria were progressively abandoned as patient populations changed and ideological pressure intensified. The NHS study, rather than accounting for this drift, appears to build on the corrupted version of the protocol rather than its carefully bounded original. Perhaps the most striking passage in the episode concerns the nine thousand children who passed through GIDS before its closure. The NHS has declined to conduct systematic follow-up on this cohort. For researchers and policymakers across the EU, that refusal should be alarming: it means a generation of patients treated under an unevaluated protocol will leave no usable long-term data. Clark also discusses the suppressed results of Tavistock's own Early Intervention Study and references an American study led by Joanna Olson-Kennedy whose findings have not been publicly released — a pattern of missing evidence that makes any new trial's claims to be filling a research gap look difficult to sustain. The exclusion of detransitioners from the NHS consultation process is another thread that runs through the discussion. Across Europe, the voices of those who regret medical transition have begun to reach parliaments and health ministries — in France, in Sweden, increasingly in Germany. Their systematic exclusion from the body of evidence that the Pathways study will rely upon is not a procedural detail; it shapes what questions the study is even designed to ask. For European listeners, this episode functions as a warning. The UK's decisions carry weight with regulators and clinicians on the continent, and a large NHS-funded trial, however flawed its design, will generate publications that will be cited. Clark's detailed analysis of where and why the study falls short is therefore not only relevant to British parents and campaigners — it is essential reading for anyone trying to understand the direction of youth gender medicine across Europe in the years ahead.
